Silence Therapeutics said this week that it has identified the maximum tolerated dose for its siRNA-based cancer treatment Atu027 and that the drug has proven safe and well-tolerated in a nearly complete phase I trial.
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now. Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
In PNAS this week: rare variants linked to bleeding disorder, comparison of whole-exome and whole-genome sequencing, and more.
George Church tells The Sunday Times that his group has inserted some woolly mammoth genes into elephant cells.
A Scientific Reports editor resigns over a new policy at the journal allowing researchers to pay to fast track the peer review of their manuscripts, and poll.
The National Cancer Institute's Harold Varmus discusses the state of cancer research with the New York Times.